Premier Inc. Statement on FAST Generics Act Last Updated: April 6, 2017
Filed under:
Print Friendly, PDF & Email

By Blair Childs, Premier, Senior Vice President of Public Affairs

Members of the Premier healthcare alliance commend Reps. Peter Welch (D-VT), David McKinley (R-WV), Kurt Schrader (D-OR) and Steve Stivers (R-OH) for introducing the Fair Access for Safe and Timely (“FAST”) Generics Act.

This legislation is critical to ongoing efforts to prevent anti-competitive behavior in the marketplace and stop some branded drug makers from blocking the introduction of generic and biosimilar medications. Specifically, the bill would expressly prohibit branded manufactures from exploiting FDA’s Risk Evaluation and Mitigation Strategies (REMS) program by establishing closed distribution networks that bar potential generic and biosimilar competitors from accessing the samples they need to conduct equivalence studies necessary for FDA approval of new drug applications. In closing this loophole, the legislation will give generic drug makers a clear pathway for market entry and unleash competitive forces that could help save $5.4 billion a year in reduced drug costs.

The FAST Generics Act is an essential tool for helping to ensure greater patient access to lifesaving therapies at the most affordable price. We are proud to support this legislation, and call on members of the House of Representatives to vote in favor of its speedy enactment.

-By Blair Childs, Premier Inc. Senior Vice President of Public Affairs